Assuming shareholders approve Lam Kong’s £8mln equity investment, the billionaire’s China Medical System company will sign a licence deal that will see it develop and commercialise Midatech’s products in South East Asia
Early data from the first-in-human study of Midatech’s acromegaly and carcinoid cancer drug, MTD201 is due within the next few months, while its, MTX110 brain cancer treatment continues to “progress well”
Midatech has said it will consider taking action to ensure it regains compliance with listing requirements on the Nasdaq exchange; at present, its US shares trade below the minimum bid price level of US$1
A fully integrated specialty pharma company, Midatech Pharma (LON:MTPH) is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug...
MTD119 is a combination of the company’s gold nanoparticle technology and the drug maytansine. It is being developed to tackle in a targeted way hepatocellular carcinoma, a rare, aggressive cancer that affects the liver and which has a poor prognosis